Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00936364 · ClinicalTrials.gov registry record · NA
Short-Term Fasting: Impact on Toxicity
A NA study, sponsored by University of Southern California.
- Terminated
- Registry status
- NA
- Development phase
- 47
- Enrollment target
NCT00936364: Clinical Trial NA study, sponsored by University of Southern California.
NCT00936364 is a NA study that was terminated before completion, run by University of Southern California. The registered enrollment target is 47 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00936364, a NA study, was terminated before completion, sponsored by University of Southern California.
- TERMINATED
- Registry status
- NA
- Development phase
- 47 participants
- Enrollment target
Study Summary
This partially randomized clinical trial studies short-term fasting in reducing side effects in patients receiving gemcitabine hydrochloride and cisplatin for advanced solid tumors. Short-term fasting before chemotherapy may reduce the side effects caused by chemotherapy. Drugs used in chemotherapy, such as gemcitabine hydrochloride and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
Interventions
- OTHER Fasting
- OTHER Short-term fasting
- OTHER Modified fast
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2009-07-09 |
| Est. Completion | 2025-05-23 |
| Phase | NA |
Why NCT00936364 stopped before completion
NCT00936364 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 47 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 3 interventions - of which Fasting is the first listed.
NCT00936364 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00936364 about?
NCT00936364 is a clinical study titled "Short-Term Fasting: Impact on Toxicity". This partially randomized clinical trial studies short-term fasting in reducing side effects in patients receiving gemcitabine hydrochloride and cisplatin for advanced solid tumors. Short-term fasting before chemotherapy may reduce the side effects caused by chemotherapy. Drugs used in chemotherapy,...
What is the current status of trial NCT00936364?
This trial is currently terminated. It is a NA study. The enrollment target is 47 participants. The study started on 2009-07-09. Estimated completion is 2025-05-23.
What interventions are being tested in trial NCT00936364?
The interventions under investigation include: Fasting (OTHER), Short-term fasting (OTHER), Modified fast (OTHER).
Who is sponsoring clinical trial NCT00936364?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00936364's enrollment target sits among peer trials
47 1400th of 2000 higher than 599 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03313011 · 47 participants
The Neurobiology of Two Distinct Types of Progressive Apraxia of Speech
- NCT03467516 · 47 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Metastatic Uveal Melanoma
- NCT03886662 · 47 participants · Phase 1
A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)
- NCT04013802 · 47 participants · Phase 1
TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI